R108
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 86
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.450
- ANGIOGENESIS+0.310
- WNT_BETA_CATENIN_SIGNALING+0.290
- OXIDATIVE_PHOSPHORYLATION+0.260
- CHOLESTEROL_HOMEOSTASIS+0.250
- MYC_TARGETS_V1+0.250
- NOTCH_SIGNALING+0.220
- P53_PATHWAY+0.180
- ESTROGEN_RESPONSE_EARLY+0.160
- ESTROGEN_RESPONSE_LATE+0.160
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.590
- INTERFERON_GAMMA_RESPONSE-0.530
- ALLOGRAFT_REJECTION-0.330
- INFLAMMATORY_RESPONSE-0.310
- IL6_JAK_STAT3_SIGNALING-0.280
- PROTEIN_SECRETION-0.280
- COMPLEMENT-0.260
- PI3K_AKT_MTOR_SIGNALING-0.230
- MITOTIC_SPINDLE-0.210
- HEME_METABOLISM-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR11296875 | — | — | 0.847 |
| 2 | aMVAC.P_013_TURBT_S232 | — | — | 0.822 |
| 3 | 701e70ac-31d2-4e78-95e1-3fa2bb466e83 | — | — | 0.808 |
| 4 | TCGA-UY-A78M-01A-21R-A352-07 | — | — | 0.789 |
| 5 | R92 | — | — | 0.785 |
| 6 | add96e53-1114-4364-979b-641665d16629 | — | — | 0.773 |
| 7 | DRR168602 | — | — | 0.757 |
| 8 | SJEPD037_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.755 |
| 9 | 124c158a-8435-4f81-b84e-89ccc4bb53f1 | — | — | 0.751 |
| 10 | TCGA-XF-AAMH-01A-11R-A42T-07 | — | — | 0.750 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.450 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.310 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.290 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.250 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.250 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.180 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.160 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.140 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.090 | Idelalisib | — uncovered |
| COAGULATION | 0.080 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.070 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |